MedTrace Logo

Remimazolam Phase II Cardiac Anesthesia Study

NCT01937767 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-01-18

No results posted yet for this study

Summary

This phase II study in patients undergoing elective cardiac surgery will evaluate the efficacy, safety, and pharmacokinetics of remimazolam, compared with propofol and sevoflurane, during the induction and maintenance of general anesthesia.

Conditions

  • General Anesthesia

Interventions

DRUG

Remimazolam

DRUG

Propofol

DRUG

Sevoflurane

DRUG

Remifentanil

DRUG

Fentanyl

DRUG

Rocuronium

Sponsors & Collaborators

  • Aptiv Solutions

    collaborator INDUSTRY

  • Paion UK Ltd.

    lead INDUSTRY

Principal Investigators

  • Stefan Probst, MD · Heart Center Leipzig - University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-02-28
Completion
2014-02-19

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937767 on ClinicalTrials.gov